<DOC>
	<DOCNO>NCT00737893</DOCNO>
	<brief_summary>This research study aim explore effectiveness human erythropoietin versus placebo promote recovery erectile function patient undergoing bilateral nerve-sparing radical retropubic prostatectomy clinically localized prostate cancer . Pre-clinical study rat model show erythropoietin potently promote recovery erectile function . The hypothesis erythropoietin offer nerve protection men undergo nerve-sparing radical prostatectomy result reduced time erectile dysfunction also improve rate erection recovery follow surgery .</brief_summary>
	<brief_title>Erythropoietin Enhance Erection Recovery Men Following Radical Prostatectomy</brief_title>
	<detailed_description>This study evaluate effectiveness erythropoietin versus placebo recovery erectile function patient undergoing bilateral nerve-sparing radical prostatectomy prostate cancer . Recent laboratory finding suggest , erythropoietin may play role protection cavernous nerve surgery . Some degree nerve trauma occur bilateral nerve-sparing radical prostatectomy , temporary . erythropoietin study investigational drug enhancement erectile function postoperatively . The length study 12 month involve receive dose study drug placebo day surgery , day surgery , day follow surgery . The dose give subcutaneous injection . The study also require completion questionnaire mail , email , do online every three month study completion .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patient eligibility consist men 40 65 year age Localized prostate cancer clinical stage &lt; T2a Gleason grade &lt; 7 prostate specific antigen ( PSA ) &lt; 10 Scheduled undergo curative prostatectomy apply bilateral nervesparing procedure , intact presurgical erectile function International Index Erectile Function [ IIEF ] , erectile function domain score &gt; 26 Otherwise meeting follow exclusion/inclusion criterion . The patient sexual partner , least 6 month . The patient 's presurgical hematocrit â‰¤ 48 . The patient answer 56 time great question # 6 IIEF . The patient know penile deformity history Peyronie 's disease . The patient pre post operative androgen therapy . The patient pre post operative radiation therapy . The patient anticoagulation therapy . The patient history sickle cell anemia . The patient history high low blood pressure control . The patient take medication call `` nitrate '' The patient history heart problem angina , heart failure , irregular heartbeat , myocardial infarction The patient history history drug alcohol abuse . The patient currently smoke 20 pack/year history cigarette smoking . The patient history acute chronic depression The patient history liver problem , kidney problem . The patient history retinitis pigmentosa severe vision loss , include condition call NAION , Nonarteritic Anterior Ischemic Optic Neuropathy . The patient history spinal trauma surgery brain spinal cord . The patient contraindication use phosphodiesterase type 5 ( PDE 5 ) inhibitor . Patient currently participate another clinical investigation would serve contraindication administer erythropoietin .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>Radical Prostatectomy</keyword>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>